Compare · APLT vs RUBY
APLT vs RUBY
Side-by-side comparison of Applied Therapeutics Inc. (APLT) and Rubius Therapeutics Inc. (RUBY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. APLT focuses on Biotechnology: Pharmaceutical Preparations, while RUBY focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- RUBY is the larger of the two at $574.2M, about 8.1x APLT ($70.8M).
- APLT has more recent analyst coverage (11 ratings vs 4 for RUBY).
- Company
- Applied Therapeutics Inc.
- Rubius Therapeutics Inc.
- Price
- $0.11+5.91%
- $0.09-26.81%
- Market cap
- $70.8M
- $574.2M
- 1M return
- +3.66%
- -
- 1Y return
- -72.67%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 11
- 4
Applied Therapeutics Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Rubius Therapeutics Inc.
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest APLT
- SEC Form 15-12G filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Skyler Jay S returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Funtleyder Leslie D. was granted 1,187,500 shares and returned 2,375,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Bailey Evan Prescott returned 1,235,915 shares to the company and was granted 437,500 shares, closing all direct ownership in the company (SEC Form 4)
- Director Lerner Teena returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest RUBY
- SEC Form 15-12G filed by Rubius Therapeutics Inc.
- SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)
- Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 25 filed by Rubius Therapeutics Inc.
- SEC Form DEF 14A filed by Rubius Therapeutics Inc.
- Stocks That Hit 52-Week Lows On Monday
- Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket